DALLAS, July 16, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring oncology drug maker Genta Inc. (GETA). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Genta Inc. (OTCBB:GETA) should be of particular interest to other biotechnology companies: ISIS Pharmaceuticals Inc. (Nasdaq:ISIS), AVI BioPharma Inc. (Nasdaq:AVII), Enzo Biochem Inc. (NYSE:ENZ) and Bio-Reference Laboratories Inc. (Nasdaq:BRLI).
It is available at: http://investorsoup.com/lp/GNTA/
Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/
Genta Inc. (OTCBB:GETA) operates as a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer. Its research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules. The Company's lead compound from its DNA/RNA Medicines program is Genasense (oblimersen sodium) injection that is designed to block the production of a protein, known as Bcl-2, which is a fundamental cause of the inherent resistance of cancer cells to anticancer treatments, such as chemotherapy, radiation and monoclonal antibodies.
In the report, the analyst notes:
"GETA announced preliminary results from its ongoing clinical study of tesetaxel, a oral taxane in the Company's investigational drug portfolio. The new data show a favorable safety profile with a low incidence of serious adverse events, along with objective responses that have been observed at less than the maximally tolerated dose (MTD).
"GETA reported preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Company's lead oncology product, Genasense (oblimersen sodium) Injection, in a chemotherapy program for patients with advanced melanoma."
To read the entire report visit: http://investorsoup.com/lp/GNTA/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup, please visit http://www.InvestorSoup.com
InvestorSoup Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.
CONTACT: InvestorSoup.com
Jeffrey Brown, Editor
(469)-252-3505
info@investorsoup.com
